Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 29, 2026Pediatric Blood & Cancer

Current Approaches Among Medical Providers Treating Pediatric Langerhans Cell Histiocytosis

View Full Paper
Ask AI
Bookmark
Share

Authors

LMLauren K. MeyerOAOussama AblaCACarl E. Allen

Discussion

Loading...

Member takes

Overview

Survey reveals treatment practices and clinical trial design preferences for MAPK inhibitors in pediatric LCH.

Key Points

  • To explore how medical providers integrate MAPK inhibitors in pediatric LCH treatment and their views on clinical trials.
  • Distributed an online survey to members of key medical societies.
  • Included questions on demographics, treatment experience, and trial design preferences.
  • Surveyed 106 pediatric attending physicians from 26 countries.
  • 79% of providers with MAPK inhibitor access have used them for treating recurrent/refractory LCH.
  • 90% agreed on the necessity of prospective trials for newly diagnosed LCH patients.
  • 83% supported combining MAPK inhibitors with chemotherapy in clinical trials.

Cite This Study

Meyer et al. (2026) studied this question.

synapsesocial.com/papers/6a69a2e2c8da07d9defa6db0https://doi.org/10.1002/1545-5017.70525
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy, safety, and relapse outcomes of <scp>MAPK</scp> inhibitors in pediatric Langerhans cell histiocytosis: A real‐world study2025 · 2 citations
  2. 2Clinical, radiological and molecular responses to combination chemotherapy with <scp>MAPK</scp> pathway inhibition in relapsed and refractory Langerhans cell histiocytosis2024 · 17 citations
  3. 3Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH2023 · 33 citations
  4. 4Histiocyte Society blueprint for Langerhans cell histiocytosis research: from cell-of-origin to a more comprehensive cure2025 · 1 citations
  5. 5The importance of patient-reported outcomes in clinical trials and strategies for future optimization2018 · 695 citations